Monitor for the NDA submission in Q1 2027 and potential partnership or licensing deals that could extend cash runway. The stock is likely to trade on clinical catalysts rather than quarterly financial results.
Price Chart
Executive Summary
PMV Pharma reported Q1 2026 net loss per share of -$0.34, in line with the year-ago period and beating consensus estimates of -$0.39, though the company remains pre-revenue. Clinical progress continued with rezatapopt NDA submission on track for Q1 2027 and cash runway to end of Q2 2027. The filing is routine with no material change in financial trajectory.
Key Financial Metrics
Key Facts
- Net loss per share of -$0.34 (unchanged YoY) on net loss of $18.0M
- Cash, cash equivalents, and marketable securities of $93.5M as of March 31, 2026
- Net cash used in operations was $19.7M in Q1 2026 vs $18.3M in Q1 2025
- NDA submission for rezatapopt in platinum-resistant/refractory ovarian cancer on track for Q1 2027
- Orphan Drug Designation granted by FDA for rezatapopt in TP53 Y220C positive ovarian cancer
Financial Impact
No revenue; net loss $18.0M vs $17.4M YoY; cash burn increase of ~$1.4M
Risk Factors
- Clinical trial failure or regulatory delay for rezatapopt
- Cash runway only to end of Q2 2027, requiring financing before NDA approval
- No approved products and no revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-218225 |
| Document: pmvp-20260512.htm | 0001193125-26-218225 |
| Document: 0001193125-26-218225-index-headers.html | 0001193125-26-218225 |
| Document: 0001193125-26-218225-index.html | 0001193125-26-218225 |
| Document: 0001193125-26-218225.txt | 0001193125-26-218225 |
| 8-K Data (Synthetic) | 0001193125-26-218225 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 8-K | $1.78 | awaiting T+20 | — | $1.13 (−36.52%) |
Aug 31, 2026 8w ago | Press Release | $1.29 $1.67 | ▼ −29.46% | ▼ −29.14% | $1.13 (+12.40%) |
Aug 31, 2026 8w ago | 8-K | $1.29 $1.67 | ▲ +29.46% | ▲ +29.14% | $1.13 (−12.40%) |
Aug 31, 2026 8w ago | Press Release | $1.29 $1.67 | ▼ −29.46% | ▼ −29.14% | $1.13 (+12.40%) |
Aug 31, 2026 8w ago | Press Release | $1.29 $1.67 | ▲ +29.46% | ▲ +29.14% | $1.13 (−12.40%) |
Aug 14, 2026 10w ago | 8-K | $1.26 $1.46 | ▲ +15.87% | ▲ +17.86% | $1.13 (−10.32%) |
Aug 14, 2026 10w ago | Press Release | $1.26 $1.46 | ▲ +15.87% | ▲ +17.86% | $1.13 (−10.32%) |
May 12, 2026 23w ago | 8-K | $1.42 $1.06 | ▼ −25.35% | ▼ −23.62% | $1.13 (−20.42%) |
May 12, 2026 23w ago | Press Release | $1.42 $1.06 | ▼ −25.35% | ▼ −23.62% | $1.13 (−20.42%) |
Apr 22, 2026 26w ago | DEFA14A | $1.48 $1.31 | ▼ −11.49% | ▼ −14.65% | $1.13 (−23.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers